KAZIA THERAPEUTICS LIMITED(KZA)

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

The company notifies ASIC of the appointment or cessation of a director or company secretary.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares.

delisted at entity's request under Listing Rule 17.11

we understand the board decided to delist because the administrative time, costs and commercial disadvantages of the listing outweighed the benefits - the company remains listed on NASDAQ

The securities of Kazia Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of KZA, to facilitate its removal from the official list of ASX Limited.

The suspension of trading in the securities of Kazia Therapeutics Limited will be lifted immediately following the release by KZA of an announcement regarding its proposed delisting on the Official List of ASX.

Kazia advises that it has submitted a formal application to the ASX to be removed from the official list of the ASX in accordance with ASX Listing Rule 17.11. This formal request follows the receipt of in-principle advice from the ASX in relation to the proposed Delisting, subject to the satisfaction of some conditions.

The securities of Kazia Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of KZA, pending the release of an announcement regarding the proposed trading solely on Nasdaq and proposed delisting of KZA's securities from ASX.

The suspension of trading in the securities of Kazia Therapeutics Limited will be lifted immediately, following the release by KZA of an announcement regarding a capital raising.

The company completes a placement of KZA shares, primarily to sector-specialist institutional investors in Australia and internationally, at a price of A$0.38 per share. The placement will raise approximately A$3.4 million. Kazia will launch a share purchase plan to allow eligible existing holders of KZA securities the opportunity to acquire new fully-paid ordinary shares on the same terms as the placement. The SPP will open on Tuesday 23 October 2018.

The securities of Kazia Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of KZA, pending the release of an announcement regarding a potential capital raising.

name changed from Novogen Limited